Edinburgh Cancer Research Centre: A History of Innovation in Medical Oncology
The Edinburgh Cancer Research Centre (ECRC) stands as a testament to the evolution of cancer care and scientific inquiry in Scotland. From its humble beginnings in a portable cabin to its current status as a hub for translational research—the process of turning laboratory discoveries into clinical treatments—the centre has played a pivotal role in improving the lives of cancer patients.
The Foundation of Medical Oncology in Edinburgh
The journey began in 1978 when the Imperial Cancer Research Fund (ICRF), a prominent UK cancer research charity, provided an £800,000 endowment to establish a Chair of Medical Oncology within the Faculty of Medicine in Edinburgh. Following a competitive selection process, John F. Smyth was appointed to the position on April 1, 1979. After a brief tenure at the University of Chicago, Professor Smyth officially assumed his duties in Edinburgh on October 1, 1979, marking the formal inception of the centre.
To support this new academic leadership, the University of Edinburgh and the Lothian Health Board (NHS) collaborated to create the city's first clinical service for medical oncology. This service was initially based at the Western General Hospital, utilizing dedicated beds and outpatient facilities.
[ไม่มีภาพประกอบ]
Early Growth and Research Focus
By 1980, the facility was formally recognized as the Imperial Cancer Research Fund Medical Oncology Unit in Edinburgh, with Professor Smyth serving as director. This recognition brought additional funding, leading to the 1981 commissioning of a small research laboratory housed in a portable cabin on the Western General Hospital campus.
The Unit's primary objectives were twofold: developing more effective drug therapies for all types of cancer and discovering new methods to mitigate the side effects of anti-cancer medications.
Scientific Breakthroughs and Expansion
With sustained support from the ICRF and other organizations, the Unit expanded its capacity to conduct clinical trials for promising therapeutics. One of its most significant contributions was conducting the first clinical trial of a 5-HT3 receptor antagonist. This breakthrough fundamentally changed the management of emesis (nausea and vomiting) associated with cancer treatment.
As research activities grew, the Unit relocated in 1984 to the top floor of the MRC Human Genetics Unit building. Following a successful review in 1996, it became clear that further growth required a purpose-built facility. Professor Smyth led fundraising efforts that resulted in a £7 million building, which was officially opened by The Princess Royal in 2002.
This new facility provides 3,000 square meters of gross internal space and serves as the primary base for ECRC researchers. In 2002, coinciding with a university reorganization, the entity was renamed the Edinburgh Cancer Research Centre. By 2007, the ECRC became part of the Institute of Genetics and Molecular Medicine.
Partnerships with Cancer Research UK
The ECRC has maintained a long-standing relationship with Cancer Research UK (CRUK), the successor to the ICRF. In 2004, the ECRC hosted the CRUK Clinical Cancer Centre. This evolved in 2010 into the CRUK Edinburgh Centre, a "virtual" partnership between the ECRC, the NHS, and other local research sites designed to accelerate translational research.
Due to a reduction in income during the COVID-19 pandemic, CRUK restructured its network in 2022. While funding for the specific Edinburgh Centre ended, the ECRC remains a partner in the new CRUK Scotland Centre, based at The Beatson Institute for Cancer Research in Glasgow. Additionally, in 2018, the ECRC partnered with the University College London Cancer Institute to establish the CRUK Brain Tumour Centre of Excellence.
Key Facts
- Established: October 1, 1979.
- Founding Director: Professor John F. Smyth.
- Major Milestone: Conducted the first clinical trial of 5-HT3 receptor antagonists for emesis control.
- Infrastructure: A £7M purpose-built facility opened in 2002 providing 3,000 square meters of space.
- Current Affiliation: Partner in the CRUK Scotland Centre and the CRUK Brain Tumour Centre of Excellence.
| Period | Director(s) |
|---|---|
| 1980 – 2005 | John Smyth |
| 2005 – 2009 | David Harrison |
| 2010 – 2020 | Margaret Frame (Science) & David Cameron (Clinical) |
| 2020 – 2023 | Ian Tomlinson (Director) & Charlie Gourley (Clinical) |
| 2023 – Present | Charlie Gourley (Clinical Director) |
Frequently Asked Questions
How did the Edinburgh Cancer Research Centre start?
It began in 1979 after the Imperial Cancer Research Fund provided an £800,000 endowment to create a Chair of Medical Oncology at the University of Edinburgh, led by Professor John F. Smyth.
What was the ECRC's contribution to cancer patient comfort?
The centre was responsible for the first clinical trial of a 5-HT3 receptor antagonist, which led to dramatic improvements in controlling nausea and vomiting (emesis) caused by cancer treatments.
What is the current relationship between ECRC and Cancer Research UK?
While the specific CRUK Edinburgh Centre funding ended in 2022, the ECRC is now a partner in the CRUK Scotland Centre and continues to collaborate via the CRUK Brain Tumour Centre of Excellence.
Where is the ECRC located?
The centre is based in a purpose-built 3,000 square meter facility opened in 2002, and it is part of the Institute of Genetics and Molecular Medicine.
Who is the current Clinical Director of the ECRC?
As of 2023, Charlie Gourley serves as the Clinical Director.